Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Inclusion Criteria: * Ability to communicate with medical team and staff, willingness to participate in the study, give written informed consent, comply with the study restrictions * Adults aged 18 years, inclusive, or older * Treatment for cancer with Intervenous cisplatin once every 21 or 28 days * Plan to receive a minimum cumulative dose of cisplatin of ≥ 280 mg/m2 over at least three cycles * Concomitant use of other chemotherapy and radiation is permitted except investigational agents and/or radiation \> 35 Grays involving the cochlear area * Male patients, their female partner(s), and female patients of childbearing potential must agree to use 2 forms of contraception, 1 of which must be a barrier method, during the study and for 90 days after the last study drug administration. * Male and female patients who consider themselves abstinent, and who agree to remain abstinent during the study and for 90 days after the last study drug administration * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 * Anticipated survival \> 1 year * Normal or not clinically significant otoscopic findings in both ears * Patient has read, understood, and voluntarily signed the informed consent form. Exclusion Criteria: * Female or male patients with female partners who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days after last dose of study drug * Prior treatment with a cisplatin regimen * Signs of disturbed integr…